Increasing the sample size when the unblinded interim result is promising

Increasing the sample size based on unblinded interim result may inflate the type I error rate and appropriate statistical adjustments may be needed to control the type I error rate at the nominal level. We briefly review the existing approaches which allow early stopping due to futility, or change the test statistic by using different weights, or adjust the critical value for final test, or enforce rules for sample size recalculation. The implication of early stopping due to futility and a simple modification to the weighted Z‐statistic approach are discussed. In this paper, we show that increasing the sample size when the unblinded interim result is promising will not inflate the type I error rate and therefore no statistical adjustment is necessary. The unblinded interim result is considered promising if the conditional power is greater than 50 per cent or equivalently, the sample size increment needed to achieve a desired power does not exceed an upper bound. The actual sample size increment may be determined by important factors such as budget, size of the eligible patient population and competition in the market. The 50 per cent‐conditional‐power approach is extended to a group sequential trial with one interim analysis where a decision may be made at the interim analysis to stop the trial early due to a convincing treatment benefit, or to increase the sample size if the interim result is not as good as expected. The type I error rate will not be inflated if the sample size may be increased only when the conditional power is greater than 50 per cent. If there are two or more interim analyses in a group sequential trial, our simulation study shows that the type I error rate is also well controlled. Copyright © 2004 John Wiley & Sons, Ltd.

[1]  J. Wittes On changing a long‐term clinical trial midstream , 2002, Statistics in medicine.

[2]  J. Denne,et al.  Sample size recalculation using conditional power , 2001, Statistics in medicine.

[3]  A L Gould,et al.  Sample size re‐estimation: recent developments and practical considerations , 2001, Statistics in medicine.

[4]  W. Shih Sample size re‐estimation – journey for a decade , 2001, Statistics in medicine.

[5]  Z. Shun,et al.  Type I error in sample size re‐estimations based on observed treatment difference , 2001, Statistics in medicine.

[6]  M. Proschan,et al.  Internal pilot studies I: type I error rate of the naive t-test. , 1999, Statistics in medicine.

[7]  D. DeMets,et al.  The agonising negative trend in monitoring of clinical trials , 1999, The Lancet.

[8]  L Fisher,et al.  Statistical Inference for Self‐Designing Clinical Trials with a One‐Sided Hypothesis , 1999, Biometrics.

[9]  S. Lorentsen,et al.  Estimation of offspring production from a limited number of stage-structured censuses. , 1999, Biometrics.

[10]  L D Fisher,et al.  Self-designing clinical trials. , 1998, Statistics in medicine.

[11]  J. Long,et al.  Blinded sample size re-estimation with unequal variances and center effects in clinical trials , 1998 .

[12]  W J Shih,et al.  Design for sample size re-estimation with interim data for double-blind clinical trials with binary outcomes. , 1997, Statistics in medicine.

[13]  W J Shih,et al.  Re-evaluating design specifications of longitudinal clinical trials without unblinding when the key response is rate of change. , 1995, Statistics in medicine.

[14]  M. Proschan,et al.  Designed extension of studies based on conditional power. , 1995, Biometrics.

[15]  S. Day,et al.  Internal pilot studies for estimating sample size. , 1994, Statistics in medicine.

[16]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[17]  D L DeMets,et al.  Monitoring of clinical trials: issues and recommendations. , 1993, Controlled clinical trials.

[18]  Monitoring of clinical trials and interim analyses from a drug sponsor's point of view. , 1993, Statistics in medicine.

[19]  A. Gould,et al.  Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance , 1992 .

[20]  K Kim,et al.  Sample size determination for group sequential clinical trials with immediate response. , 1992, Statistics in medicine.

[21]  A L Gould,et al.  Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. , 1992, Statistics in medicine.

[22]  J. Wittes,et al.  The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.

[23]  K K Lan,et al.  The B-value: a tool for monitoring data. , 1988, Biometrics.

[24]  D L Demets,et al.  Practical aspects in data monitoring: a brief review. , 1987, Statistics in medicine.

[25]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[26]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[27]  S. Pocock Group sequential methods in the design and analysis of clinical trials , 1977 .